Dan Stanton

Roche inked a $1.5 billion deal for off-the-shelf CAR-T partner Poseida Therapeutics in a week that saw its peer Novartis buy gene therapy developer Kate Therapeutics.

Under its “One Lonza” strategy, the CDMO will exit the capsules space to focus on three business units: Integrated Biologics, Advanced Synthesis, and Specialized Modalities.

Healthcare-focused investment firm Altaris will snap up the advanced therapies unit, including five UK and US-based facilities, from WuXi AppTec.

Merck & Co. (known as MSD outside North America) will buy the manufacturing facility in County Louth, Ireland from its contract manufacturing partner WuXi Vaccines.

BioXconomy presents the Asia biopharma and healthcare dealmaking and financing news for the week ending 5 January.

Whether mAbs, mRNA, gene therapies, exosomes, or vaccines, third-party manufacturers are intrinsic to drug development. BioProcess Insider therefore brings you the latest CDMO deals.

Indian CDMO Aragen has laid out aggressive expansion plans for capacity and multi-modality services following a $100 million investment from Singapore-based private equity (PE) fund Quadria Capital.

With a mix of feasibility study alliances, R&D collaborations, and outright M&A, Novo Nordisk’s presence in the RNA and gene therapy space now complements its core peptide and protein portfolio.

BioXconomy presents the Asia biopharma and healthcare dealmaking and financing news for the week ending 19 January.

Approximately 20% of bioreactor runs over 30 months were rejected due to contamination issues at Sanofi’s Framingham biologics facility, according to the US FDA.